Description:
The overall purpose of this study is to explore the therapeutic effect of CD123-targeted
chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
Title
- Brief Title: A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
- Official Title: A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Clinical Trial IDs
- ORG STUDY ID:
TMMU-BTC-008
- NCT ID:
NCT02937103
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Anti-CD123-CAR-transduced T cells | CD123-targeted CAR-T cells | Myeloid Malignancies |
Purpose
The overall purpose of this study is to explore the therapeutic effect of CD123-targeted
chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
Detailed Description
Great progress has been made in the treatment of relapsed and refractory B cell malignancies
with CD19-targeted CAR-T cells. However, for myeloid malignancies, which has higher
morbidity, trials of CAR-T is few. CD123 is expressed on most myeloid leukemia cells so it is
a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia
stem cells, which indicates that the eradication of CD123+ cells may prevent relapse of
leukemia. This trial is designed and conducted to test the safety and effectiveness of
CD123-targeted CAR-T.
Trial Arms
Name | Type | Description | Interventions |
---|
Myeloid Malignancies | Experimental | The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited. | - Anti-CD123-CAR-transduced T cells
|
Eligibility Criteria
Inclusion Criteria:
1. CD123-expressing myeloid malignancy must be assured and must be relapsed or refractory
disease. According to current traditional therapies, there must be no available
alternative curative therapies and subjects must be either ineligible for allogeneic
stem cell transplant (SCT), have refused SCT, or have disease activity that prohibits
SCT at this time.
2. Patients enrolled must have an evaluated score above 60 with KPS.
3. CD123 expression of the malignant cells must be detected by immunohistochemistry or by
flow cytometry.
4. Gender is not limited, age from 14 years to 75 years.
5. Patients must have measurable or evaluable disease at the time of enrollment, which
may include any evidence of disease including minimal residual disease detected by
flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
6. Patients are expected to survive for more than 3 months by their physicians at the
time of enrollment.
7. Adequate absolute CD3 count estimated need to be assured for obtaining target cell
dose based on dosage cohorts.
8. Subjects with the following CNS status are eligible only in the absence of neurologic
symptoms suggestive of CNS leukemia, such as cranial nerve palsy:
CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin
preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL
WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by
Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic
and intensive IT chemotherapy (and therefore not eligible for radiation)
9. Ability to give informed consent.
10. Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by
MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or
left ventricular ejection fraction greater than or equal to 50% by ECHO.
11. Renal function: Creatinine level of peripheral blood is required no greater than
133umol/L.
12. Females of child-bearing potential must have a negative pregnancy test because of the
potentially dangerous effects on the fetus.
13. Patients with history of allogeneic stem cell transplantation are eligible if there is
no evidence of active GVHD and no longer taking immunosuppressive agents for at least
30 days prior to enrollment.
14. Patients volunteer to participate in the research.
Exclusion Criteria:
1. Evident signs suggesting that patients are potentially allergic to cytokines.
2. Frequent infection history and recent infection is uncontrolled.
3. Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi
anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure
syndrome
4. Active acute or chronic graft-versus-host disease (GVHD) or requirement of
immunosuppressant medications for GVHD within 4 weeks of enrollment.
5. Concurrent use of systemic steroids or chronic use of immunosuppressant medications.
Recent or current use of inhaled steroids is not exclusionary. For additional details
regarding use of steroid and immunosuppressant medications.
6. Pregnancy and nursing females.
7. HIV infection.
8. Active hepatitis B or active hepatitis C.
9. Participation in a prior investigational study within 4 weeks prior to enrollment or
longer if required by local regulation. Participation in non-therapeutic research
studies is allowed.
10. Class III/IV cardiovascular disability according to the New York Heart Association
Classification.
11. Patients with a known history or prior diagnosis of other serious immunologic,
malignant or inflammatory disease.
12. Other situations we think not eligible for participation in the research.
Maximum Eligible Age: | 75 Years |
Minimum Eligible Age: | 14 Years |
Eligible Gender: | All |
Healthy Volunteers: | Accepts Healthy Volunteers |
Primary Outcome Measures
Measure: | Adverse Events That Are Related to Treatment |
Time Frame: | 3 years |
Safety Issue: | |
Description: | Determine the toxicity profile of the CD123 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0. |
Secondary Outcome Measures
Measure: | In vivo existence of Anti-CD123 CAR-T cells |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Measure: | Reaction Rate of Treatment |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Southwest Hospital, China |
Trial Keywords
- Leukemia
- Myeloid
- CD123
- CAR-T
Last Updated
June 25, 2019